Patents Assigned to Rosalind Franklin University of Medicine and Science
-
Patent number: 10011578Abstract: Disclosed herein are methods and compositions comprising compounds capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, and aging-related CNS disorders.Type: GrantFiled: August 8, 2017Date of Patent: July 3, 2018Assignee: Rosalind Franklin University of Medicine and ScienceInventors: Grace E. Stutzmann, Russell Dahl, Christopher H. Kaiho
-
Patent number: 9970056Abstract: Network-based meta-analysis of four independent microarray studies identified the hepatocyte nuclear factor (HNF4A), a transcription factor associated with gluconeogenesis and diabetes, as a central regulatory hub gene upregulated in blood of PD patients. In parallel, the polypyrimidine tract binding protein 1 (PTBP1), involved in the stabilization and mRNA translation of insulin, was identified as the most downregulated gene. Using both markers, PD patients were classified with 90% sensitivity and 80% specificity. Longitudinal performance analysis demonstrated that relative abundance of HNF4A and PTBP1 mRNAs significantly decreased and increased, respectively, in PD patients during 3 years follow up period. The inverse regulation of HNF4A and PTBP1 provides a molecular rationale for the altered insulin signaling observed in PD patients. The longitudinally dynamic biomarkers identified in this study may be useful for monitoring disease-modifying therapies for PD.Type: GrantFiled: September 30, 2015Date of Patent: May 15, 2018Assignee: Rosalind Franklin University of Medicine and ScienceInventors: Judith Ann Potashkin, Jose Alfredo Santiago
-
Publication number: 20180117073Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.Type: ApplicationFiled: December 8, 2017Publication date: May 3, 2018Applicant: Rosalind Franklin University of Medicine and ScienceInventor: Michelle L. Hastings
-
Publication number: 20180119152Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.Type: ApplicationFiled: December 8, 2017Publication date: May 3, 2018Applicant: Rosalind Franklin University of Medicine and ScienceInventor: Michelle L. HASTINGS
-
Patent number: 9840710Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease.Type: GrantFiled: November 11, 2016Date of Patent: December 12, 2017Assignees: Rosalind Franklin University of Medicine and Science, The McLean Hospital CorporationInventors: Michelle L. Hastings, Ole Isacson, Joanna A. Korecka-Roet
-
Patent number: 9839389Abstract: The present disclosure provides a device for testing the strength of a human foot. The device includes a substantially planar member having a top surface and a bottom surface. The device also includes a foot-engaging member moveable along the top surface substantially planar member from a first position to a second position. In addition, the device includes a force sensor fixed with respect to the substantially planar member, where the force sensor resists movement between the first position and the second position. Further, the device includes a tension bearing element connecting the foot-engaging member to the force sensor.Type: GrantFiled: April 17, 2015Date of Patent: December 12, 2017Assignee: Rosalind Franklin University of Medicine and ScienceInventor: Karen Marie Stevens
-
Patent number: 9840709Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.Type: GrantFiled: February 17, 2016Date of Patent: December 12, 2017Assignee: Rosalind Franklin University of Medicine and ScienceInventor: Michelle L. Hastings
-
Patent number: 9827478Abstract: The present disclosure is directed to a body-worn sensor-based system for evaluating the biomechanics and the motor adaptation characteristics of postural control during a sport activity such as a golf swing. Various embodiments use sensors such as accelerometers, gyroscopes, and magnetometers to measure the three-dimensional motion of ankle and hip joints. In several embodiments, additional sensors attached to other body segments are used to improve the accuracy of the data or detect particular instants during the swing (e.g., top of back swing, instant of the maximum speed of arm, and instant of ball impact). In a golf embodiment, the system combines the measured data in conjunction with a biomechanical model of the human body to: (1) estimate the two-dimensional sway of the golfer's center of mass; (2) quantify and evaluate the golfer's balance via his/her postural compensatory strategy; and (3) provide visual feedback to the golfer for improving dynamic postural control.Type: GrantFiled: February 6, 2015Date of Patent: November 28, 2017Assignees: BOISENSICS LLC, ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCEInventors: Bijan Najafi, James Stanley Wrobel, Ali-Reza Boloori
-
Publication number: 20170268000Abstract: The present invention provides compounds comprising oligonucleotides complementary to a CLN3 transcript. Certain such compounds are useful for hybridizing to a CLN3 transcript, including but not limited to a CLN3 transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CLN3 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Batten Disease.Type: ApplicationFiled: December 2, 2014Publication date: September 21, 2017Applicants: Ionis Pharmaceuticals, Inc., Rosalind Franklin University of Medicine and ScienceInventors: Frank RIGO, Michelle L. HASTINGS
-
Patent number: 9753042Abstract: The present invention provides a kit for determining male fertility including a container system containing a plurality of enzyme-linked antibodies one of each capable of binding to analytes Atp6v0a2, G-CSF, MIP 1?, and MCP-1. The kit further includes suitable packaging and a set of instructions for using the enzyme-linked antibodies with a seminal sample to determine the fertility of the sample.Type: GrantFiled: April 22, 2014Date of Patent: September 5, 2017Assignee: Rosalind Franklin University of Medicine and ScienceInventor: Kenneth Beaman
-
Patent number: 9725429Abstract: Disclosed herein are methods and compositions comprising compounds of formula (I) capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, and aging-related CNS disorders.Type: GrantFiled: May 19, 2015Date of Patent: August 8, 2017Assignee: Rosalind Franklin University of Medicine and ScienceInventors: Grace E. Stutzmann, Russell Dahl, Christopher H. Kaiho
-
Publication number: 20170191066Abstract: The present invention provides compounds comprising oligonucleotides complementary to an LRP8 transcript. Certain such compounds are useful for hybridizing to an LRP8 transcript, including but not limited, to an LRP8 transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRP8 transcript. In certain embodiments, such hybridization results in an increase in inclusion of exon 19 in the LRP8 mRNA transcript. In certain embodiments, such compounds are used to treat Alzheimer's Disease.Type: ApplicationFiled: June 4, 2015Publication date: July 6, 2017Applicants: Ionis Pharmaceuticals, Inc., Rosalind Franklin University of Medicine and ScienceInventors: Frank Rigo, Michelle L. Hastings
-
Patent number: 9556434Abstract: The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length within exon 3 of an Usher RNA transcript.Type: GrantFiled: May 6, 2015Date of Patent: January 31, 2017Assignee: Rosalind Franklin University of Medicine and ScienceInventor: Michelle L Hastings
-
Patent number: 9532961Abstract: The present invention provides a method for preventing blood-brain barrier reperfusion injury in a mammalian blood-brain barrier endothelial cell during reperfusion following ischemic stroke comprising administering an effective amount of a ?-glutamyl-D-cysteine antioxidant to the subject and a kit for doing the same.Type: GrantFiled: April 23, 2013Date of Patent: January 3, 2017Assignee: Rosalind Franklin University of Medicine and ScienceInventor: Darryl R Peterson
-
Publication number: 20160244833Abstract: Network-based meta-analysis of four independent microarray studies identified the hepatocyte nuclear factor (HNF4A), a transcription factor associated with gluconeogenesis and diabetes, as a central regulatory hub gene upregulated in blood of PD patients. In parallel, the polypyrimidine tract binding protein 1 (PTBP1), involved in the stabilization and mRNA translation of insulin, was identified as the most downregulated gene. Using both markers, PD patients were classified with 90% sensitivity and 80% specificity. Longitudinal performance analysis demonstrated that relative abundance of HNF4A and PTBP1 mRNAs significantly decreased and increased, respectively, in PD patients during 3 years follow up period. The inverse regulation of HNF4A and PTBP1 provides a molecular rationale for the altered insulin signaling observed in PD patients. The longitudinally dynamic biomarkers identified in this study may be useful for monitoring disease-modifying therapies for PD.Type: ApplicationFiled: September 30, 2015Publication date: August 25, 2016Applicant: Rosalind Franklin University of Medicine and ScienceInventors: Judith Ann POTASHKIN, Jose Alfredo SANTIAGO
-
Publication number: 20160244832Abstract: Increasing evidence indicates that Parkinson's disease (PD) and type 2 diabetes (T2DM) share dysregulated molecular networks. 84 genes shared between PD and T2DM were identified from curated disease-gene databases. Nitric oxide biosynthesis, lipid and carbohydrate metabolism, insulin secretion and inflammation were identified as common dysregulated pathways. A network prioritization approach was implemented to rank genes according to their distance to seed genes and their involvement in common biological pathways. This disclosure reinforces the idea that shared molecular networks between PD and T2DM provide an additional source of biologically meaningful biomarkers.Type: ApplicationFiled: September 30, 2015Publication date: August 25, 2016Applicant: Rosalind Franklin University of Medicine and ScienceInventors: Judith Ann POTASHKIN, Jose Alfredo SANTIAGO
-
Publication number: 20160244767Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.Type: ApplicationFiled: February 17, 2016Publication date: August 25, 2016Applicant: Rosalind Franklin University of Medicine and ScienceInventor: Michelle L. HASTINGS
-
Publication number: 20160193167Abstract: The present invention provides a method for preventing blood-brain barrier reperfusion injury in a mammalian blood-brain barrier endothelial cell during reperfusion following ischemic stroke comprising administering an effective amount of a ?-glutamyl-D-cysteine antioxidant to the subject and a kit for doing the same.Type: ApplicationFiled: April 23, 2013Publication date: July 7, 2016Applicant: Rosalind Franklin University of Medicine and ScienceInventor: Darryl R. PETERSON
-
Patent number: 9353371Abstract: The present invention provides compounds comprising oligonucleotides complementary to an Usher transcript. Certain such compounds are useful for hybridizing to an Usher transcript, including but not limited, to an Usher transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the Usher transcript. In certain such embodiments, the Usher transcript includes a mutation that results in cryptic splicing and hybridization of the oligonucleotide results in a decrease in the amount of cryptic splicing. In certain embodiments, such compounds are used to treat Usher Syndrome.Type: GrantFiled: May 2, 2012Date of Patent: May 31, 2016Assignees: Ionis Pharmaceuticals, Inc., Rosalind Franklin University of Medicine and ScienceInventors: Michelle L. Hastings, Frank Rigo, C. Frank Bennett
-
Patent number: 9327017Abstract: The present invention provides a composition for delivering a protein vaccination candidate to a mammalian subject having a Leishmania transfected for expressing a cDNA sequence for encoding the protein vaccination candidate, and the Leishmania containing a photosensitizer.Type: GrantFiled: May 10, 2012Date of Patent: May 3, 2016Assignee: Rosalind Franklin University of Medicine and ScienceInventors: Kwang-Poo Chang, Sujoy Dutta